8AP Stock Overview A biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Agios Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Agios Pharmaceuticals Historical stock prices Current Share Price US$34.20 52 Week High US$58.00 52 Week Low US$19.40 Beta 0.77 1 Month Change -34.86% 3 Month Change -17.39% 1 Year Change 66.02% 3 Year Change 11.29% 5 Year Change -24.02% Change since IPO 60.30%
Recent News & Updates Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
New minor risk - Share price stability Nov 17
Investor sentiment improves as stock rises 25% Nov 09
Third quarter 2024 earnings released: EPS: US$16.65 (vs US$1.64 loss in 3Q 2023) Nov 01
Agios Pharmaceuticals, Inc. Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease Oct 25
Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib Aug 07 See more updates Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
New minor risk - Share price stability Nov 17
Investor sentiment improves as stock rises 25% Nov 09
Third quarter 2024 earnings released: EPS: US$16.65 (vs US$1.64 loss in 3Q 2023) Nov 01
Agios Pharmaceuticals, Inc. Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease Oct 25
Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib Aug 07
New minor risk - Profitability Aug 03
Second quarter 2024 earnings released: US$1.69 loss per share (vs US$1.51 loss in 2Q 2023) Aug 02
New major risk - Revenue and earnings growth Aug 01
Agios Pharmaceuticals, Inc. Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused Aug 01
New minor risk - Profitability Jul 24
Agios Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 18
Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress Jun 15
Forecast to breakeven in 2024 Jun 15
Agios Pharmaceuticals, Inc. Announces Phase 3 Energize-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia Jun 05
First quarter 2024 earnings released: US$1.45 loss per share (vs US$1.47 loss in 1Q 2023) May 03
Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024 Apr 28
New minor risk - Shareholder dilution Apr 28
Full year 2023 earnings released: US$6.33 loss per share (vs US$4.23 loss in FY 2022) Feb 18
Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024 Feb 03
Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio Jan 09
Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition Dec 11
Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes Nov 21
Third quarter 2023 earnings released: US$1.64 loss per share (vs US$1.49 loss in 3Q 2022) Nov 03
Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Nov 02
Second quarter 2023 earnings released: US$1.51 loss per share (vs US$1.68 loss in 2Q 2022) Aug 04
Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 14
Agios Pharmaceuticals, Inc. Announces Board Changes May 26 Agios Pharmaceuticals, Inc. Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition
Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023 Dec 07
Agios Pharmaceutical's PYRUKYND® Approves in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients Nov 11
Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022 Sep 20
Agios Pharmaceuticals, Inc. Receives Positive Chmp Opinion for Pyrukynd® (Mitapivat) for the Treatment of Pyruvate Kinase (Pk) Deficiency in Adult Patients Sep 18
Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022 Sep 08
Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors Aug 16
Agios Pharmaceuticals, Inc. Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent a- and ß-Thalassemia Aug 12
Insufficient new directors Aug 09 Agios Pharmaceuticals, Inc. Announces Management Changes, Effective August 8, 2022
Agios Presents New Clinical Data Supporting the Benefits of Pyrukynd® Treatment in Adults with PK Deficiency At European Hematology Association Annual Congress Jun 11
Agios Pharmaceuticals, Inc. Announces Resignation of Bruce Car as Chief Scientific Officer, effective as of August 1, 2022 May 28
Agios Pharmaceuticals, Inc. Announces Management Changes May 19
Agios Pharmaceuticals, Inc. Announces Executive Changes May 17
Insufficient new directors Apr 27
Agios Pharmaceuticals, Inc. Announces Resignation of Ian T. Clark from the Board Apr 27
Agios Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 22
Agios Pharmaceuticals, Inc. Announces FDA Approval of Pyrukynd (Mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency Feb 18
No longer forecast to breakeven Jan 13
No longer forecast to breakeven Dec 31 Agios Pharmaceuticals, Inc. Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition
Chief Commercial Officer Darrin Miles has left the company Dec 06
Insufficient new directors Dec 06
Forecast to breakeven in 2021 Sep 23
Agios Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency Aug 18
Principal Accounting Officer and VP of Accounting, Treasury & Tax Carman Alenson has left the company Aug 04 Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) dropped from Russell Midcap Value Index
Agios Pharmaceuticals, Inc. Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency Jun 22 Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Study of Mitapivat in Non-Transfusion-Dependent a- and ß-Thalassemia at the European Hematology Association Virtual Congress
Insider recently sold €158k worth of stock May 19
Agios Reports Clinical Data Presentations Apr 30
Agios Pharmaceuticals, Inc. Announces Closing of Oncology Business Sale to Servier Apr 03
Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma Mar 03
Full year 2020 earnings released: US$4.75 loss per share (vs US$6.86 loss in FY 2019) Feb 26
Revenue beats expectations Feb 26
Agios Pharmaceuticals, Inc. Announces the Appointment of Darrin Miles to Role of Chief Commercial Officer Feb 26
New 90-day high: €47.53 Feb 12
Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused Jan 28
New 90-day high: €40.87 Jan 27
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma Jan 19
Servier Pharmaceuticals, LLC entered into a definitive agreement to acquire oncology business from Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) for $2 billion. Dec 23
New 90-day low: €27.94 Dec 11
Agios Pharmaceuticals, Inc. Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused Dec 02
Agios Pharmaceuticals, Inc. Launches Anemia ID Dec 01
New 90-day high: €38.08 Nov 24
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease Nov 13
Third quarter 2020 earnings released: US$1.43 loss per share Nov 06
Revenue misses expectations Nov 06
Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia Oct 18
New 90-day low: €30.71 Sep 23
Agios Pharmaceuticals, Inc. Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO Sep 22
New 90-day low - €35.15 Aug 11 Shareholder Returns 8AP DE Biotechs DE Market 7D -5.5% -2.9% -2.6% 1Y 66.0% -14.7% 6.9%
See full shareholder returns
Return vs Market: 8AP exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is 8AP's price volatile compared to industry and market? 8AP volatility 8AP Average Weekly Movement 10.6% Biotechs Industry Average Movement 6.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 8AP's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8AP's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria.
Show more Agios Pharmaceuticals, Inc. Fundamentals Summary How do Agios Pharmaceuticals's earnings and revenue compare to its market cap? 8AP fundamental statistics Market cap €1.94b Earnings (TTM ) €646.26m Revenue (TTM ) €31.50m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 8AP income statement (TTM ) Revenue US$32.87m Cost of Revenue US$299.46m Gross Profit -US$266.58m Other Expenses -US$940.89m Earnings US$674.31m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 11.82 Gross Margin -811.00% Net Profit Margin 2,051.38% Debt/Equity Ratio 0%
How did 8AP perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 22:02 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Agios Pharmaceuticals, Inc. is covered by 32 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Peter Lawson Barclays George Farmer BMO Capital Markets Equity Research Alec Stranahan BofA Global Research
Show 29 more analysts 
